Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphatic Diseases × Bendamustine Hydrochloride × Clear all

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 24 Leukemia, Lymphocytic, Chronic, B-Cell 23 Lymphoma, Mantle-Cell 22 Lymphoma, Non-Hodgkin 21 Lymphoma, Follicular 17 Multiple Myeloma 14 Lymphoma, Large B-Cell, Diffuse 13 Recurrence 12 Hodgkin Disease 8 Leukemia 7 Waldenstrom Macroglobulinemia 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Neoplasms, Plasma Cell 4 Neoplasms 4 Lymphoma, B-Cell, Marginal Zone 4 Leukemia, B-Cell 4 Lymphoma, T-Cell 3 Leukemia, Lymphoid 3 Hematologic Neoplasms 3 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, B-Cell 2 Leukemia, Myeloid, Acute 2 Burkitt Lymphoma 2 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Sarcoma 1 Renal Insufficiency, Chronic 1 Renal Insufficiency 1

Interventions

Cyclophosphamide 5 blinatumomab 4 Rituximab 3 Brentuximab Vedotin 3 fludarabine phosphate 2 fludarabine 2 dacetuzumab 2 cobomarsen 2 Whole-Body Irradiation 2 Vincristine 2 Tacrolimus 2 Prednisone 2 Peripheral Blood Stem Cell Transplantation 2 Patient Reported Outcome Measures 2 Mycophenolic Acid 2 Mesna 2 Melphalan 2 Ifosfamide 2 Everolimus 2 Etoposide 2 Doxorubicin 2 Carboplatin 2 Busulfan 2 sepantronium 1 pomalidomide 1 pembrolizumab 1 Vorinostat 1 DTRMWXHS-12 1 Bone Marrow Transplantation 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02499627 2021-05-27

FIL-BBV

Fondazione Italiana Linfomi - ETS

Phase 2 Terminated

Lymphatic Diseases, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡